Variable | Baseline value | Range | Reference | Distribution | |
---|---|---|---|---|---|
Minimum | Maximum | ||||
Weibull survival model of OS of PEP Weibull survival model of OS of EP | Scale = 0.035532, Shape = 1.209467 Scale = 0.021012, Shape = 1.497332 | – – | – – | [10] | – – |
Weibull survival model of PFS of PEP Weibull survival model of PFS of EP | Scale = 0.06893, Shape = 1.40287 Scale = 0.02532, Shape = 2.21179 | - – | – – | [10] | – – |
Risk for main adverse events in PEP group | |||||
 Risk of neutropenia | 0.435 | 0.348 | 0.522 | [10] | Beta |
 Risk of anemia | 0.157 | 0.126 | 0.189 | [10] | Beta |
 Risk of thrombocytopenia | 0.139 | 0.111 | 0.167 | [10] | Beta |
 Risk of leucopenia | 0.117 | 0.094 | 0.140 | [10] | Beta |
 Risk of pneumonia | 0.067 | 0.054 | 0.080 | [10] | Beta |
Risk for main adverse events in EP group | |||||
 Risk of neutropenia | 0.408 | 0.326 | 0.490 | [10] | Beta |
 Risk of anemia | 0.152 | 0.121 | 0.182 | [10] | Beta |
 Risk of thrombocytopenia | 0.112 | 0.090 | 0.134 | [10] | Beta |
 Risk of leucopenia | 0.094 | 0.075 | 0.113 | [10] | Beta |
Utility | |||||
 Utility PFS in first-line treatment | 0.840 | 0.672 | 1.008 | [12] | Beta |
 Utility PD | 0.473 | 0.378 | 0.568 | [13] | Beta |
Disutility due to AEs | |||||
 Neutropenia | 0.09 | 0.072 | 0.108 | [13] | Beta |
 Anemia | 0.073 | 0.058 | 0.088 | [13] | Beta |
 Leucopenia | 0.09 | 0.072 | 0.108 | [13] | Beta |
 Pneumonia | 0.09 | 0.072 | 0.108 | [14] | Beta |
Thrombocytopenia | 0.02 | 0.016 | 0.024 | [15] | Beta |
Drug cost, $/per mg | |||||
 Pembrolizumab | 20,370.80 | 16,296.64 | 24,444.96‬ | [20] | Gamma |
 Etoposide | 1,663.73 | 1,330.98 | 1996.47 | [20] | Gamma |
 Carboplatin | 85.83 | 68.66 | 103.00 | [20] | Gamma |
 Cisplatin | 51.78 | 41.42 | 62.13 | [20] | Gamma |
 Topotecan | 199.87 | 159.90 | 239.84 | [20] | Gamma |
Expenditures on main adverse events, $ | |||||
 Leucopenia | 6,831.97 | 5,465.58 | 8,198.37 | [21] | Gamma |
 Neutropenia | 733.36 | 586.69 | 880.03 | [22] | Gamma |
 Anemia | 1,199.86 | 959.89 | 1,439.83 | [22] | Gamma |
 Thrombocytopenia | 851.51 | 681.21 | 1,021.82 | [22] | Gamma |
 Pneumonia | 5,646.88 | 4,517.51 | 6,776.26 | [22] | Gamma |
Laboratory per cycle | 315.14 | 252.11 | 378.17 | [23] | Gamma |
Tumor imaging per cycle | 231.10 | 184.88 | 167.60 | [24] | Gamma |
Administration per cycle | 139.67 | 111.74 | 167.60 | [25] | Gamma |
Discount rate | 0.03 | – | – | [11] | – |